Sugi Predict

Sugi Predict / Compounds / Asparagine

Asparagine

Asparagine

SCHEMBL2927424

CC(C)[C@H](N)C(N)=O.C[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.O=C(O)[C@@H]1[C@H](c2ccc3ccccc3c2)CC[N+]12C(=O)CCC2=O

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SLC1A3 P43003 1/20 0.32
▸ SLC1A2 P43004 1/20 0.32
▸ SLC1A1 P43005 1/20 0.32
▸ GRIK1 P39086 1/20 0.31
▸ GRIK2 Q13002 1/20 0.31
▸ GRIK3 Q13003 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL7855644 0.95 SLC1A3 (0.34) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
Asparagine SCHEMBL2902140 0.88 — —
Asparagine SCHEMBL2902050 0.79 SLC1A3 (0.34) SLC1A3SLC1A2SLC1A1
Asparagine SCHEMBL2902137 0.71 MC4R (0.35) —
Asparagine SCHEMBL7855451 0.65 MC4R (0.36) —
Asparagine SCHEMBL28219869 0.61 SLC7A5 (0.52) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
Asparagine SCHEMBL8892690 0.60 SLC7A5 (0.58) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
Asparagine SCHEMBL8892693 0.60 SLC7A5 (0.58) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
Dl-Phenylalanine SCHEMBL28019412 0.58 SLC7A5 (0.69) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
Asparagine SCHEMBL286918 0.58 SLC7A5 (0.56) SLC1A3SLC1A2SLC1A1GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2239270-A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2010-10-13 — — EP disclosed
EP-1845106-B1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 — — EP disclosed
EP-1845106-A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2007-10-17 — — EP disclosed
EP-1157040-B1 LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-22 — — EP disclosed
US-6365572-B1 FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-02 — — US disclosed
EP-1070727-A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction Aventis Pharma Deutschland GmbH (DE) 2001-01-24 — — EP disclosed